Institutional members access full text with Ovid®

Share this article on:


Mehta, Lahar, R.; Goodman, Andrew, D.

doi: 10.1212/01.CON.0000293644.43858.54

The introduction of disease-modifying therapies has revolutionized the care of patients with multiple sclerosis (MS). Currently six agents have been specifically approved for use in MS. These include three formulations of interferon beta, glatiramer acetate, mitoxantrone, and natalizumab. Evidence supporting their use includes demonstrable impact on relapse rate, MRI measures of lesion activity and accumulation, as well as (in some cases) a favorable impact on disability progression.

© 2007 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website